Germany-based Evotec SE (NASDAQ:EVO) is trading on Monday after a report that suggests the company is a takeover target. The ...

Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to ...

Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...

Evotec price target lowered to EUR 11.60 from EUR 12 at RBC Capital Evotec rallies after Bloomberg says Triton weighing takeover bid Evotec Reports Strategic Growth Amidst Revenue Challenges Evotec AG ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...

Evotec shares soared after the company said private equity group Triton had acquired about 10% of its stock. Luxembourg-based private equity firm Triton acquired a total of 17,730,913 ordinary shares ...

Shares in Evotec jumped as much as 13.3% on Monday after regulatory filings showed private equity firm Triton had built an over 9% stake in the German drug development company.

German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.

Evotec’s struggles have put it in the crosshairs of private equity groups. After seeing the company’s share price fall around ...

ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...

Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...